University of Leicester
Browse
Published pdf.pdf (900.84 kB)

Type 2 Diabetes and Impaired Physical Function: A Growing Problem

Download (900.84 kB)
journal contribution
posted on 2022-03-11, 15:57 authored by Ehtasham Ahmad, Jack A Sargeant, Tom Yates, David R Webb, Melanie J Davies
The focus in diabetes care has traditionally been around the optimisation of the glycaemic control and prevention of complications. However, the prevention of frailty and improvement in physical function have now emerged as new targets of diabetes management. This is mainly driven by the significant adverse impact that early onset frailty and decline in physical function have on health outcomes, functional independence, and quality of life in people with type 2 diabetes (T2D). There is an increasing emphasis in the expert consensus and management algorithms to improve physical function in people with T2D, predominantly through lifestyle interventions, including exercise and the control of modifiable risk factors. Trials of novel glucose-lowering therapies (GLTs) also now regularly assess the impact of these novel agents on measures of physical function within their secondary outcomes to understand the impact that these agents have on physical function. However, challenges remain as there is no consensus on the best method of assessing physical function in clinical practice, and the recognition of impaired physical function remains low. In this review, we present the burden of a reduced physical function in people with T2D, outline methods of assessment used in healthcare and research settings, and discuss strategies for improvement in physical function in people with T2D.

Funding

J.A.S. received a grant in support of an investigator-initiated trial from AstraZeneca. T.Y. is supported by the NIHR Leicester BRC and received funding from Astra Zeneca for an investigator initiated project. D.R.W. received honoraria as a speaker for AstraZeneca, Sanofi-Aventis, and Lilly, and received research funding support from Novo Nordisk. M.J.D. acted as a consultant, advisory board member, and speaker for Novo Nordisk, Sanofi, Lilly, and Boehringer Ingelheim, an advisory board member and speaker for AstraZeneca, an advisory board member for Janssen, Lexicon, Pfizer, Servier, and Gilead Sciences Ltd., and as a speaker for Napp Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International Inc. She has received grants in support of investigator and investigator-initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca, and Janssen.

History

Citation

Ahmad, E.; Sargeant, J.A.; Yates, T.;Webb, D.R.; Davies, M.J., Type 2 Diabetes and Impaired Physical Function: A Growing Problem. Diabetology 2022, 3, 30–45. https://doi.org/10.3390/diabetology3010003

Author affiliation

NIHR Leicester Biomedical Research Centre

Version

  • VoR (Version of Record)

Published in

Diabetology

Volume

3

Issue

1

Pagination

30 - 45

Publisher

MDPI AG

eissn

2673-4540

Acceptance date

2022-01-06

Copyright date

2022

Available date

2022-03-11

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC